Cardiff Oncology Inc.
3.30
-0.17 (-4.90%)
At close: Jan 14, 2025, 3:59 PM
3.30
0.02%
Pre-market Jan 15, 2025, 06:56 AM EST
undefined%
Bid 3.3
Market Cap 219.48M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -0.95
PE Ratio (ttm) -3.47
Forward PE n/a
Analyst Buy
Ask 3.54
Volume 801,670
Avg. Volume (20D) 2,113,286
Open 3.54
Previous Close 3.47
Day's Range 3.28 - 3.57
52-Week Range 1.44 - 6.42
Beta undefined

About CRDF

Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevac...

Industry Biotechnology
Sector Healthcare
IPO Date Jul 27, 2004
Employees 31
Stock Exchange NASDAQ
Ticker Symbol CRDF

Analyst Forecast

According to 3 analyst ratings, the average rating for CRDF stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 203.08% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Cardiff Oncology Inc. is scheduled to release its earnings on Feb 27, 2025, during market hours.
Analysts project revenue of $73.00K, reflecting a -53.21% YoY shrinking and earnings per share of -0.26, making a 23.81% increase YoY.
1 month ago · Source
+19.88%
Cardiff Oncology shares are trading higher after P... Unlock content with Pro Subscription
1 month ago · Source
+54.92%
Cardiff Oncology shares are trading higher after the company announced the initial data from its CRDF-004 Phase 2 trial evaluating Onvansertib.